Dr. David Williams, Chief of the Division of Hematology & Oncology at Boston Children’s Hospital, Associate Chairman of the Department of Pediatric Oncology at the Dana-Farber Cancer Institute, and Leland Fikes Professor of Pediatrics at Harvard Medical School

March 15, 2024

In this episode, we discuss advances in gene therapy and its use in treating pediatric patients. Using modified viruses as delivery vehicles, researchers and clinicians can target therapies to specific types of cells, providing patients with long-lasting—and potentially life-long—treatments for a variety of severe genetic conditions. Future advances hope to make these therapies less expensive, less invasive, and more accessible for patients around the world and to expand their use for more common conditions.

Dr. Adam Leman, Lead Scientist, Fermentation, Good Food Institute

December 19, 2023

In this episode, we discuss the convergence of fermentation, perhaps the world's oldest biotechnology, with modern advancements in molecular biology to produce non-animal proteins as a sustainable food source. The exponential growth of the human population and our continued reliance on traditional processes for growing crops and raising animals for food risk widespread food security challenges, as we approach the limit of Earth's arable land. Cutting-edge biotechnology tools and novel applications of ancient fermentation processes allow us to modify bacteria, fungi, and other organisms, so we can leverage their unique properties to produce sustainable and nutritious—and tasty!—alternatives to animal-based proteins.

Dr. James Diggans, Head of Biosecurity, Twist Bioscience & Chair, International Gene Synthesis Consortium

October 19, 2023

In this episode, we discuss the role of international screening efforts in protecting against the misuse of synthetically manufactured genetic materials. Rapid expansion in the capacity, affordability, and accessibility of gene synthesis—the ability to assemble genetic sequences from scratch—enables anyone with an internet connection to order custom genomes from vendors around the world. In the absence of consistent national or global regulatory frameworks, the responsibility falls on gene synthesis companies and researchers themselves to ensure that these services are not being misused to produce dangerous pathogens or their components. The International Gene Synthesis Consortium (IGSC) is an industry organization that supports the development and implementation of screening protocols for gene synthesis orders and customers to mitigate the risk of this misuse, in order to facilitate the broadest use of these technologies for peaceful purposes.